Investors.rexahn.com

Investor S Rexahn. Inc.'s business for stockholders, potential investors, and financial analysts.

What’s new on Investors.rexahn.com: Check updates and related news right now. Unfortunately, we cannot detect RSS feed on this website, but you may observe related news or Investors.rexahn.com popular pages instead. It is generally safe for browsing, so you may click any item to proceed to the site.

News, stories and media buzz related to Investor S Rexahn

Subscribe to related news

Rexahn Pharmaceuticals Strengthens Leadership Team
via investingnews

ROCKVILLE, Md., July 11, 2016 (GLOBE NEWSWIRE) — Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced the appointment of Lisa Nolan...
Rexahn Pharma Receives a Buy from FBR Capital
via analystratings

FBR Capital analyst Vernon Bernardino reiterated a Buy rating on Rexahn Pharma (NYSE MKT: RNN) yesterday and set a price target of $3. The company’s shares opened today at $0.16, close to its 52-week low of $0.14. Bernardino wrote: “On November 7,...
Deals Of The Week: Kicking The Tires
via invivoblog.blogspot

Apparently, virtually by the time it became “news,” it transformed into “non-news.” News reports of Roche’s interest in acquiring ultra-rare disease focused Alexion Pharmaceuticals surfaced suddenly July 12 and just as rapidly...
Daiichi Sankyo’s Rare Cancer Drug Receives Breakthrough Therapy Designation from the FDA
via spjnews

Parsippany, NJ and Berkeley, CA – (October 30, 2015) – Daiichi Sankyo, Inc. and Plexxikon Inc., a member of the Daiichi Sankyo Group, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its...
Atheronova, Inc. (AHRO: OTCQB) | AtheroNova Initiates Phase 1 Clinical Trial of AHRO-001, a Potential Treatment for Athe...
via hotstockcafe

IRVINE, Calif., June 25, 2013 /PRNewswire/ — AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement...